Cargando…

Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?

Detalles Bibliográficos
Autores principales:	Badagliacca, Roberto, Sciomer, Susanna, Petrosillo, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Society for Heart and Lung Transplantation. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162760/ https://www.ncbi.nlm.nih.gov/pubmed/32360293 http://dx.doi.org/10.1016/j.healun.2020.04.007

Ejemplares similares

Endothelin receptor antagonist and airway dysfunction in pulmonary arterial hypertension
por: Droste, Annette S, et al.
Publicado: (2009)

Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension
por: Steiner, M Kathryn, et al.
Publicado: (2008)

Polypharmacy in the Management of Arterial Hypertension—Friend or Foe?
por: Diaconu, Camelia Cristina, et al.
Publicado: (2021)

VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension
por: Hamidi, Sayyed A, et al.
Publicado: (2011)

Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand?
por: Correale, Michele, et al.
Publicado: (2018)

Pulmonary arterial hypertension outcomes upon endothelin-1 receptor antagonist switch to macitentan
por: Tynan, Timothy, et al.
Publicado: (2019)

Treatment of pulmonary arterial hypertension with the dual endothelin receptor antagonist macitentan: clinical evidence and experience
por: Belge, Catharina, et al.
Publicado: (2019)

Endothelin B Receptor Immunodynamics in Pulmonary Arterial Hypertension
por: Tabeling, Christoph, et al.
Publicado: (2022)

The Growing Role of Echocardiography in Pulmonary Arterial Hypertension Risk Stratification: The Missing Piece
por: Miotti, Cristiano, et al.
Publicado: (2021)

Endothelin Receptors and Their Antagonists()()
por: Maguire, Janet J., et al.
Publicado: (2015)

Autophagy in pulmonary fibrosis: friend or foe?
por: Hill, Charlotte, et al.
Publicado: (2021)

Heme on Pulmonary Malaria: Friend or Foe?
por: Pádua, Tatiana Almeida, et al.
Publicado: (2020)

The safety of endothelin receptor antagonists in the treatment of pulmonary arterial hypertension: Protocol for a systemic review and network meta-analysis
por: Gu, Zhi-Chun, et al.
Publicado: (2018)

Current Status of Endothelin Receptor Antagonists in Pulmonary Arterial Hypertension: A Combined Study Results and Pharmacology-Based Review
por: Nahar, Shamsun, et al.
Publicado: (2023)

Human Herpesvirus 8 and Pulmonary Hypertension
por: Nicastri, Emanuele, et al.
Publicado: (2005)

Insights into Endothelin Receptors in Pulmonary Hypertension
por: Liu, Ruiqi, et al.
Publicado: (2023)

ZEB Proteins in Leukemia: Friends, Foes, or Friendly Foes?
por: Soen, Bieke, et al.
Publicado: (2018)

The role of endothelin-1 in pulmonary arterial hypertension
por: Chester, Adrian H., et al.
Publicado: (2014)

Friend and Foe
Publicado: (1890)

The COVID-19 facemask: Friend or foe?
por: Hallock, Geoffrey G.
Publicado: (2021)

Testosterone in COVID-19: Friend or Foe?
por: Niemann, Peter J., et al.
Publicado: (2021)

Estrogen and COVID-19: friend or foe?
por: Di Vincenzo, A., et al.
Publicado: (2021)

Toll-like receptor 4 in COVID-19: friend or foe?
por: Mukherjee, Suprabhat
Publicado: (2022)

Oxygen for the Newborn: Friend or Foe?
por: Perrone, Serafina, et al.
Publicado: (2023)

Macrophages: friend or foe in idiopathic pulmonary fibrosis?
por: Zhang, Lei, et al.
Publicado: (2018)

CRTH2 in Pulmonary Fibrosis: Friend or Foe?
por: He, Chao, et al.
Publicado: (2022)

Microcirculation and mean arterial pressure: friends or foes?
por: Hamzaoui, Olfa, et al.
Publicado: (2020)

Continued poxvirus research: From foe to friend
por: Bidgood, Susanna R.
Publicado: (2019)

Peripheral Arterial Stiffness in Acute Pulmonary Embolism and Pulmonary Hypertension at Short-Term Follow-Up
por: Papa, Silvia, et al.
Publicado: (2021)

Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?
por: Opitz, Christian F., et al.
Publicado: (2008)

The efficiency of endothelin receptor antagonist bosentan for pulmonary arterial hypertension associated with congenital heart disease: A systematic review and meta-analysis
por: Kuang, Hong-Yu, et al.
Publicado: (2018)

Role of cardiopulmonary exercise test in the prediction of hemodynamic impairment in patients with pulmonary arterial hypertension
por: Pezzuto, B., et al.
Publicado: (2022)

Endothelin Receptor Antagonists in Kidney Disease
por: Martínez-Díaz, Irene, et al.
Publicado: (2023)

The Aryl Hydrocarbon Receptor in Asthma: Friend or Foe?
por: Poulain-Godefroy, Odile, et al.
Publicado: (2020)

Glucocorticoids in COVID19; a friend not foe
por: Owlia, Sina, et al.
Publicado: (2020)

The immune system and COVID-19: Friend or foe?
por: Yazdanpanah, Fereshteh, et al.
Publicado: (2020)

Saliva—Friend and Foe in the COVID-19 Outbreak
por: Han, Pingping, et al.
Publicado: (2020)

Azithromycin in patients with COVID-19: Friend or foe?
por: Kow, Chia Siang, et al.
Publicado: (2021)

Innate T cells in COVID-19: friend or foe?
por: van der Heide, Verena
Publicado: (2020)

Monocytes and macrophages in COVID-19: Friends and foes
por: Meidaninikjeh, Sepideh, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_rs6m0hvb3rsvqg8oei463vrllo